Glaukos
 |
|
| Public | |
| Traded as | : GKOS |
| Industry | Health care |
| Founded | 2001 |
| Founder |
|
| Headquarters | San Clemente, California, United States |
|
Key people
|
Thomas Burns (President and CEO) |
| Revenue |
 US$45,600,000 (2014) |
 US$14,100,000 (loss) (2014) |
|
|
Footnotes / references financial information |
|
Glaukos Corporation is a glaucoma treatment company based in Laguna Hills, California. Thomas Burns is Glaukos' president and CEO.
Glaukos developed the "iStent" titanium micro-stent. The device, which is about the width of a human hair, is implanted during cataract surgery to reduce intraocular pressure. As of 2015[update], the iStent was the smallest device ever approved by the United States Food and Drug Administration. The availability of the iStent led to the addition of two codes to the Current Procedural Terminology set in 2015, 0191T and 0376T.
In 2015, Glaukos planned to transition from private company status to become a public company with an initial public offering (IPO) of company stock. The proposed stock symbol for the company was "GKOS".
Glaukos' president and chief executive officer (CEO) Thomas Burns says Glaukos was the first to develop micro-stents for the treatment of glaucoma and is well ahead of its competitors. The CEO of MicroOptx, Chris Pulling, has stated that Glaukos is his "most direct" competitor.
Founded in 2001 by Olav Bergheim, Richard Hill and Mory Gharib, the company has raised $156 million in venture funding from Versant Ventures, OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Meritech Capital Partners, Domain Associates, Fjord Capital Management and Montreux Equity Partners.
...
Wikipedia